Literature DB >> 30308438

Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms.

Sarah M Choi1, Dennis P O'Malley2.   

Abstract

The recent 2017 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues contains a number of updates under the category of lymphoid neoplasms. These changes include introduction of new entities, amended classification or terminology, and addition of newly discovered diagnostic and molecular features. In this review, we perform a focused, concise summary of selected lymphoid neoplasms and discuss changes in their classification. Rather than a comprehensive overview, we place specific emphasis on important and diagnostically relevant aspects of each entity that are novel or different from the previous WHO iteration and bring the practicing pathologist quickly up to speed with the updated classification.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  In situ neoplasia; Lymphoid neoplasms; Lymphoid tumors; Lymphoma; WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Mesh:

Year:  2018        PMID: 30308438     DOI: 10.1016/j.anndiagpath.2018.09.011

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

1.  Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome.

Authors:  Agata Sebastian; Marta Madej; Maciej Sebastian; Aleksandra Butrym; Patryk Woytala; Agnieszka Hałoń; Piotr Wiland
Journal:  Rheumatol Int       Date:  2020-02-01       Impact factor: 2.631

2.  Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.

Authors:  Ting-Zhi Liu; Yi-Jia Zheng; Zhan-Wen Zhang; Shan-Shan Li; Jiao-Ting Chen; Ai-Hua Peng; Ren-Wei Huang
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

3.  Diagnostic pitfalls: intramyocardial lymphoma metastasis mimics acute coronary syndrome in a diffuse large B cell lymphoma patient-case report.

Authors:  Lilla Prenek; Klára Csupor; Péter Beszterczán; Krisztina Boros; Erika Kardos; András Vorobcsuk; Miklós Egyed; Ádám Kellner; Péter Rajnics; Csaba Varga
Journal:  Int J Emerg Med       Date:  2021-05-07

4.  LncRNA SNHG5 can Regulate the Proliferation and Migration of Diffuse Large B Cell Lymphoma Progression via Targeting miR-181-5p/XIAP.

Authors:  Xiaojing Xing; Tonghong Xu; Bin Liu; Qianxue Guo
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

5.  High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.

Authors:  Cheng-Chih Tsai; Yung-Cheng Su; Oluwaseun Adebayo Bamodu; Bo-Jung Chen; Wen-Chiuan Tsai; Wei-Hong Cheng; Chii-Hong Lee; Shu-Min Hsieh; Mei-Ling Liu; Chia-Lang Fang; Huan-Tze Lin; Chi-Long Chen; Chi-Tai Yeh; Wei-Hwa Lee; Ching-Liang Ho; Shiue-Wei Lai; Huey-En Tzeng; Yao-Yu Hsieh; Chia-Lun Chang; Yu-Mei Zheng; Hui-Wen Liu; Yun Yen; Jacqueline Whang-Peng; Tsu-Yi Chao
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

6.  Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study.

Authors:  Wanzi Chen; Hangmin Liu; Pengcheng Wang; Guoping Li
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.